Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gentle cream outperform harsh acne drugs?

NCT ID NCT07759505

Symptom relief Sponsor: ISISPHARMA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study evaluates a new dermocosmetic cream containing 15% azelaic acid in people with mild-to-moderate acne. Researchers will observe how well the cream reduces acne lesions and improves skin discoloration, and how well it is tolerated, compared to standard treatments like oral or topical acne medications. The study follows participants over 84 days in routine care settings to see if the cream offers a comparable or better balance of effectiveness and skin tolerance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A dermocosmetic cream containing 15% azelaic acid and a complex of active ingredients
What this could lead to
If successful, this cream could offer a well-tolerated, non-prescription option for managing mild-to-moderate acne, potentially reducing reliance on stronger drugs.
What could go wrong
This is a small pilot study, so results may not apply broadly. The cream's effectiveness compared to standard treatments is uncertain, and skin irritation is a possible side effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

90 people

The number who actually took part.

Started

Sep 2022

Finished

Jun 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population was drawn from patients received by the two study investigators

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sex: female and/or male * Subject having given his/her informed written consent or parental authorization * Subject willing to adhere to the protocol and study procedures * Healthy subject with acne-prone skin: grade 2 or 3 (Global Acne Evaluation \[GEA\] scale). Exclusion Criteria: * Excluding treatment: * Epiduo® or combination of benzoyl peroxide (BPO) + Adapalene * Oral isotretinoin * Chronically used anti-inflammatory drugs * Subject manipulating his/her acneic lesions * Any change in hormonal treatment (including contraceptives) during the three previous months of the study * Cutaneous pathology on the study zone (eczema, etc) * Excessive exposure to sunlight or UV rays within the previous month * Subject enrolled in another clinical trial during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne vulgaris

Contacts and locations

Locations

  • CMI Dermato-Venerologie, Hatami Kaleshtari Mohammad

    Bucharest, 021391, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.